Robeco Institutional Asset Management B.V. Sells 13,644 Shares of BioNTech SE (NASDAQ:BNTX)

Robeco Institutional Asset Management B.V. trimmed its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 11.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 101,408 shares of the company's stock after selling 13,644 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in BioNTech were worth $11,555,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BNTX. Fred Alger Management LLC bought a new stake in BioNTech during the third quarter valued at approximately $59,485,000. Baillie Gifford & Co. boosted its stake in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after acquiring an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after acquiring an additional 7,340 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company's stock worth $15,919,000 after purchasing an additional 74,119 shares during the period. Finally, SG Americas Securities LLC raised its holdings in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after purchasing an additional 33,375 shares during the period. Institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

Shares of NASDAQ BNTX traded up $5.24 during mid-day trading on Wednesday, hitting $122.38. 870,874 shares of the company's stock traded hands, compared to its average volume of 768,203. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company's 50-day moving average is $117.33 and its two-hundred day moving average is $107.89. The company has a market capitalization of $29.34 billion, a P/E ratio of -58.28 and a beta of 0.17.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. During the same quarter in the prior year, the firm posted $0.73 earnings per share. The company's quarterly revenue was up 38.9% on a year-over-year basis. On average, equities analysts anticipate that BioNTech SE will post -3.77 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on BNTX shares. Wells Fargo & Company started coverage on BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price target for the company. Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a "buy" rating and a $130.00 target price on the stock. The Goldman Sachs Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and lifted their price target for the company from $90.00 to $137.00 in a report on Friday, November 8th. BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a research note on Monday, December 2nd. Finally, Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They set a "buy" rating and a $172.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.